Elamipretide
Elamipretide (also known as SS-31, MTP-131 and Bendavia) is a small mitochondrially-targeted tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH2) that appears to reduce the production of toxic reactive oxygen species and stabilize cardiolipin. Stealth Peptides, a privately held company, was founded in 2006 to develop intellectual property licensed from several universities including elamipretide; it subsequently changed its name to Stealth BioTherapeutics. As of November 2017 Stealth had obtained an orphan designation in the US for use in mitochondrial myopathy Mitochondrial myopathies are types of myopathy, myopathies associated with mitochondrial disease. Adenosine triphosphate (Adenosine triphosphate, ATP), the chemical used to provide energy for the cell, cannot be produced sufficiently by oxidative ... and had started a Phase III trial in that indication. As of January 2020, trial expectations were not met. References {{Reflist Tetrapeptides Experimental drugs ...
[...More Info...]       [...Related Items...]     OR:     [Wikipedia]   [Google]   [Baidu]